# EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders

> **NCT07727356** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Felix Beuschlein** · enrollment: 100 (estimated)

## Conditions studied

- Endocrine Disorders
- Hypertension
- Primary Aldosteronism
- Cortisol Excess
- Obesity & Overweight
- Healthy Adult

## Interventions

- **BEHAVIORAL:** Sequential Dietary Sodium Modulation

## Key facts

- **NCT ID:** NCT07727356
- **Lead sponsor:** Felix Beuschlein
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2031-08
- **Final completion:** 2036-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07727356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07727356, "EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07727356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*